Policy Adherence to Antithrombotic Therapy for Prophylactic Anticoagulation in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19
Overall, 40 (80%) patients were started on enoxaparin per our center's institutional guidelines. Our study demonstrated an empiric enoxaparin dose of 0.5 mg/kg (maximum initial dose 60 mg) every 12 hours resulted in zero venous thromboembolism events. In conjunction with a median dose of 3.1 mg/kg/d of aspirin, these doses resulted in one bleeding event.
Authors
- Carlton K.K. Lee
- David Procaccini (ORCID: https://orcid.org/0000-0002-8233-7218)
- Anna Sick-Samuels (ORCID: https://orcid.org/0000-0002-9247-9340)
- Amanda Clouser (ORCID: https://orcid.org/0000-0001-7028-9071)
- Courtney E. Lawrence (ORCID: https://orcid.org/0000-0002-0456-1070)
Institutions
- Hackensack University Medical Center (US)
- American Red Cross (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Johns Hopkins Children's Center (US)
Publication Details
- Journal
- The Journal of Pediatrics Clinical Practice
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1016/j.jpedcp.2025.200179
- Primary Topic
- Kawasaki Disease and Coronary Complications
- Type
- article
- Field-Weighted Citation Impact
- 0.00